Cardio Diagnostics (NASDAQ:CDIO) Posts Quarterly Earnings Results

Cardio Diagnostics (NASDAQ:CDIO) posted its earnings results on Friday. The company reported ($0.51) earnings per share for the quarter, Zacks reports. Cardio Diagnostics had a negative net margin of 36,950.00% and a negative return on equity of 78.82%.

Cardio Diagnostics Price Performance

NASDAQ CDIO traded up $0.13 on Friday, reaching $1.79. The company had a trading volume of 6,433 shares, compared to its average volume of 1,694,226. Cardio Diagnostics has a 1 year low of $0.97 and a 1 year high of $7.91. The firm has a 50-day moving average of $1.88 and a 200-day moving average of $2.14. The firm has a market capitalization of $5.30 million, a PE ratio of -0.53 and a beta of 2.27.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cardio Diagnostics in a research report on Thursday, June 11th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Cardio Diagnostics stock. DRW Securities LLC increased its position in shares of Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) by 122.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 40,463 shares of the company’s stock after buying an additional 22,298 shares during the period. DRW Securities LLC owned about 2.21% of Cardio Diagnostics worth $110,000 at the end of the most recent reporting period. 8.06% of the stock is currently owned by hedge funds and other institutional investors.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.